Can we predict the progression of premalignant pancreatic cystic tumors to ductal adenocarcinoma?
![Thumbnail](/bitstream/handle/internal/5441/fon-2021-1545.pdf.jpg?sequence=3&isAllowed=y)
View/ Open
Date
2022-06-22ICR Author
Author
Chidambaram, S
Kawka, M
Gall, TM
Cunningham, D
Jiao, LR
Type
Journal Article
Metadata
Show full item recordAbstract
Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent malignant pancreatic tumor. Few studies have shown how often PDACs arise from cystic precursor lesions. This special report aims to summarize the evidence on the progression of precancerous lesions to PDAC. A review of the literature found four studies that discussed pancreatic intraepithelial lesions (PanINs), three that discussed mucinous cystic neoplasms (MCN) and five that discussed intraductal papillary neoplasms (IPMNs). PanINs were the most common precursors lesion, with approximately 80% of PDACs originating from this lesion. The lack of evidence characterizing the features of PDAC precursor cystic lesions potentially leads to a subset of patients undergoing surgery unnecessarily. Advancements in molecular techniques could allow the study of cystic lesions at a genetic level, leading to more personalized management.
Collections
Subject
IPMN
MCN
PDAC
PanIN
pancreatic cancer
pancreatic cysts
personalized medicine
Carcinoma, Pancreatic Ductal
Humans
Pancreas
Pancreatic Neoplasms
Precancerous Conditions
Research team
Medicine (RMH)
Language
eng
Date accepted
2022-06-06
License start date
2022-06-22
Citation
Future Oncology, 2022, 18 (23), pp. 2605 - 2612
Publisher
FUTURE MEDICINE LTD
Except where otherwise noted, this item's license is described
as
https://creativecommons.org/licenses/by-nc-nd/4.0/
Related items
Showing items related by title, author, creator and subject.
-
miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial.
Khan, K; Cunningham, D; Peckitt, C; Barton, S; Tait, D; et al. (IMPACT JOURNALS LLC, 2016-03-15)BACKGROUND: Locally advanced pancreatic cancer (LAPC) is associated with high mortality, and biomarker-driven treatment approach is currently lacking. This study evaluated safety and efficacy of a combination approach of ... -
Immunotherapy and pancreatic cancer: unique challenges and potential opportunities.
Young, K; Hughes, DJ; Cunningham, D; Starling, N (2018-01)Despite decades of research, pancreatic ductal adenocarcinoma (PDAC) continues to have the worst 5-year survival of any malignancy. With 338,000 new cases diagnosed and over 300,000 deaths per year globally there is an ... -
Immunological combination treatment holds the key to improving survival in pancreatic cancer.
Sodergren, MH; Mangal, N; Wasan, H; Sadanandam, A; Balachandran, VP; et al. (2020-11)Advances in surgery, peri-operative care and systemic chemotherapy have not significantly improved the prognosis of pancreatic cancer for several decades. Early clinical trials of immunotherapy have yielded disappointing ...